35 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
29
Discovery of Potent and Selective Inhibitors of Cdc2-Like Kinase 1 (CLK1) as a New Class of Autophagy Inducers.
Sichuan University and Collaborative Innovation Center For Biotherapy
6
Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).
Icahn School Of Medicine At Mount Sinai
5
Discovery and structure of a new inhibitor scaffold of the autophagy initiating kinase ULK1.
University of California
10
A one-pot synthesis and biological activity of ageladine A and analogues.
Macquarie University
7
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
Ambit Biosciences
32
Autophagy modulation in cancer therapy: Challenges coexist with opportunities.
Sichuan University
28
Discovery of Novel SIK2/3 Inhibitors for the Potential Treatment of MEF2C+ Acute Myeloid Leukemia (AML).
Insilico Medicine Shanghai Ltd.
8
Discovery of a Novel Macrocyclic Noncovalent CDK7 Inhibitor for Cancer Therapy.
Insilico Medicine Shanghai Ltd
5
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies.
Center for Lymphoid Malignancies
8
Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.
Tufts Medical Center
1
LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.
Eli Lilly
3
A Potent and Selective ULK1 Inhibitor Suppresses Autophagy and Sensitizes Cancer Cells to Nutrient Stress.
Michigan State University
3
NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family.
Johann Wolfgang Goethe University
1
Development of potent and selective ULK1/2 inhibitors based on 7-azaindole scaffold with favorable in vivo properties.
H. Lee Moffitt Cancer Center and Research Institute
18
The mechanism of UNC-51-like kinase 1 and the applications of small molecule modulators in cancer treatment.
Shenyang Pharmaceutical University
57
Targeting autophagy drug discovery: Targets, indications and development trends.
China Jiliang University
47
The SAR and action mechanisms of autophagy inhibitors that eliminate drug resistance.
Guangzhou University of Chinese Medicine
30
Small-Molecule Drug Discovery in Triple Negative Breast Cancer: Current Situation and Future Directions.
Sichuan University
3
The Pursuit of Enzyme Activation: A Snapshot of the Gold Rush.
Baylor College of Medicine
41
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
Beijing Normal University
3
Discovery of 5-bromo-4-phenoxy-N-phenylpyrimidin-2-amine derivatives as novel ULK1 inhibitors that block autophagy and induce apoptosis in non-small cell lung cancer.
Shenyang Pharmaceutical University
26
Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.
Institute
9
ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
University of Florida
2
Structure-based rational design of staurosporine-based fluorescent probe with broad-ranging kinase affinity for kinase panel application.
Takeda Pharmaceutical
28
Design of Small Molecule Autophagy Modulators: A Promising Druggable Strategy.
China Pharmaceutical University
4
Small-Molecule Activator of UNC-51-Like Kinase 1 (ULK1) That Induces Cytoprotective Autophagy for Parkinson's Disease Treatment.
Sichuan University
30
HTS and Structure Based Optimization of Indazole-Derived ULK1 Inhibitors.
The Scripps Research Institute
5
UNC-51-like Kinase 1: From an Autophagic Initiator to Multifunctional Drug Target.
Sichuan Universitt China Hospital
25
FATTY ACID MIMETICS AS MODULATORS OF NUCLEAR RECEPTOR TLX (NR2E1)
Dartmouth College
77
2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders
Bayer